Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $12.1 million.

  • Harvard Bioscience's Receivables - Net fell 562.7% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 562.7%. This contributed to the annual value of $14.9 million for FY2024, which is 765.89% down from last year.
  • Latest data reveals that Harvard Bioscience reported Receivables - Net of $12.1 million as of Q3 2025, which was down 562.7% from $11.9 million recorded in Q2 2025.
  • Harvard Bioscience's Receivables - Net's 5-year high stood at $21.8 million during Q4 2021, with a 5-year trough of $11.9 million in Q2 2025.
  • Its 5-year average for Receivables - Net is $16.0 million, with a median of $16.1 million in 2023.
  • Its Receivables - Net has fluctuated over the past 5 years, first skyrocketed by 3214.21% in 2021, then plummeted by 2613.15% in 2024.
  • Quarter analysis of 5 years shows Harvard Bioscience's Receivables - Net stood at $21.8 million in 2021, then dropped by 23.49% to $16.7 million in 2022, then fell by 3.63% to $16.1 million in 2023, then dropped by 7.66% to $14.9 million in 2024, then fell by 18.55% to $12.1 million in 2025.
  • Its last three reported values are $12.1 million in Q3 2025, $11.9 million for Q2 2025, and $13.5 million during Q1 2025.